A computational metabolism study generated a hypothesis about lorazepam binding without demonstrating enzymatic metabolism.
The researchers built a modeled UGT2B10 structure and screened drugs relevant to pediatric stem-cell transplantation. Lorazepam was among candidate ligands prioritized through docking and molecular-dynamics procedures. The authors called for laboratory testing to determine whether candidates were substrates or inhibitors.
Predicted binding is not demonstrated turnover, inhibition, clearance, or a clinical drug interaction. The protein structure was modeled rather than obtained directly from the repository used. Selection thresholds and simulation assumptions affect which candidates appear promising.
For forensic pharmacokinetics, do not cite this paper as proof that UGT2B10 metabolizes lorazepam or explains a patient’s concentration. It supplies a testable mechanistic question. Enzyme assays, human exposure evidence, and relevant patient data would be needed to connect that hypothesis to a clinical interpretation.
Source reviewed: A potential implication of UDP glucuronosyltransferase 2B10 in the detoxification of drugs used in p (PMC8781437). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: Multimedia Bronchoscopy Information Reduced Midazolam Requirements in a Randomized Study; Lithium Toxicity, Lorazepam and Recovery: Two Treatment Processes Overlapped.